CAR-T Therapy vs Other Novel Agents for Third-Line Treatment of FL
Sarah Rutherford, MD, Weill Cornell Medicine, New York, NY, participated in a debate at the 2022 Great Debates and Updates in Hematologic Malignancies meeting discussing CAR-T therapy vs other novel agents for the treatment of early progressing follicular lymphoma (FL) after 2 lines of prior therapy.
Transcript:
My name is Sarah Rutherford. I'm an assistant professor of medicine at Weill Cornell Medicine in New York and I spoke today about a novel therapy that's very exciting for patients with FL in the third line setting, which is CAR T-cell therapy. I participated in a debate where we discussed that therapy vs other novel agents for this disease. And we're specifically talking about patients who are early progressors, so typically those who might progress after receiving therapy within 2 years.
There's really exciting data that was presented at the American Society of Hematology (ASH) meeting in 2021, and has subsequently been published, showing really excellent response rates and CR rates in the third-line setting of patients with FL treated with CAR T-cell therapy. And these responses have been durable thus far with 2 years of follow up.
In my opinion, there are many reasons why that should be the preferred treatment of patients with FL in the third-line setting. While they do have some toxicities, there are some excellent management strategies for those. And I do think that they are a superior option to some of the other newer drugs, which still do also have a role in this disease.
